[go: up one dir, main page]

CR20230132A - Inhibidores de apol1 y métodos para usar los mismos - Google Patents

Inhibidores de apol1 y métodos para usar los mismos

Info

Publication number
CR20230132A
CR20230132A CR20230132A CR20230132A CR20230132A CR 20230132 A CR20230132 A CR 20230132A CR 20230132 A CR20230132 A CR 20230132A CR 20230132 A CR20230132 A CR 20230132A CR 20230132 A CR20230132 A CR 20230132A
Authority
CR
Costa Rica
Prior art keywords
apol1
methods
inhibitors
tautomer
strong
Prior art date
Application number
CR20230132A
Other languages
English (en)
Inventor
Jun Myun Ahn
Jingrong Cao
John E Cochran
Akira Joseph Shimizu
Timothy J Senter
Suganthini S Nanthakumar
Dowd Hardwin O
Haoxuan Wang
Jon H Come
Michael Aaron Brodney
Samantha Angle
Elena Dolgikh
Steven David Stone
Brad D Maxwell
Jessica Howard Olsen
Leslie A Dakin
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CR20230132A publication Critical patent/CR20230132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona al menos una entidad elegida de los Compuestos de la Fórmula <strong>I, </strong>un tautómero del mismo, un derivado deuterado de ese compuesto o tautómero, y una sal farmacéuticamente aceptable de cualquiera de los anteriores, composiciones que comprenden los mismos, y métodos para usar los mismos, incluyendo los usos en el tratamiento de enfermedades mediadas por APOL1, incluyendo cáncer pancreático, glomeruloesclerosis segmentaria focal (FSGS), y/o enfermedad renal no diabética (NDKD). Fórmula <strong>I</strong>
CR20230132A 2020-08-26 2021-08-26 Inhibidores de apol1 y métodos para usar los mismos CR20230132A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063070705P 2020-08-26 2020-08-26
PCT/US2021/047754 WO2022047031A1 (en) 2020-08-26 2021-08-26 Inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
CR20230132A true CR20230132A (es) 2023-06-27

Family

ID=77822053

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230132A CR20230132A (es) 2020-08-26 2021-08-26 Inhibidores de apol1 y métodos para usar los mismos

Country Status (20)

Country Link
US (2) US11866446B2 (es)
EP (1) EP4204423A1 (es)
JP (1) JP2023539194A (es)
KR (1) KR20230057386A (es)
CN (1) CN116547287A (es)
AR (1) AR123355A1 (es)
AU (1) AU2021333776A1 (es)
BR (1) BR112023003423A2 (es)
CA (1) CA3190609A1 (es)
CL (1) CL2023000536A1 (es)
CO (1) CO2023003026A2 (es)
CR (1) CR20230132A (es)
DO (1) DOP2023000042A (es)
EC (1) ECSP23020167A (es)
IL (2) IL300298B1 (es)
MX (1) MX2023002269A (es)
PE (1) PE20231106A1 (es)
TW (1) TW202227456A (es)
UY (1) UY39395A (es)
WO (1) WO2022047031A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210116483A (ko) 2018-12-17 2021-09-27 버텍스 파마슈티칼스 인코포레이티드 Apol1 억제제 및 그의 사용 방법
AU2021213758A1 (en) 2020-01-29 2022-09-01 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
TWI865738B (zh) 2020-03-06 2024-12-11 美商維泰克斯製藥公司 治療apol-1依賴性局灶性節段性腎小球硬化之方法
CR20230132A (es) 2020-08-26 2023-06-27 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos
EP4392426A1 (en) * 2021-08-26 2024-07-03 Vertex Pharmaceuticals Incorporated Solid forms of spirotricyclic apol1 inhibitors and methods of using same
PE20250603A1 (es) 2022-01-18 2025-02-26 Maze Therapeutics Inc Inhibidores de apol1 y metodos de uso
EP4476227A1 (en) * 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
WO2024249252A1 (en) * 2023-05-26 2024-12-05 Maze Therapeutics, Inc. Methods of using apol1 inhibitors
WO2025059054A1 (en) 2023-09-11 2025-03-20 Vertex Pharmaceuticals Incorporated Process for preparing (2s,4s,4's,6s)-2-methyl-6-(1-methyl-1h-1,2,3-triazol-4-yl)-2',-(trieluoromethyl)-4',5'-dihydrospiro[piperidine-4,7'-thieno [2,3-c] pyran] -4'-ol

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
WO1998006720A1 (fr) 1996-08-09 1998-02-19 Eisai Co., Ltd. Derives de benzopiperidine
WO2001017965A2 (en) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines as pesticides
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
CA2424222A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
AU2005226759A1 (en) 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
CA2666406A1 (en) 2006-10-16 2008-04-24 Gruenenthal Gmbh Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators
CN101563324A (zh) 2006-12-22 2009-10-21 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
ES2454966T3 (es) 2007-02-01 2014-04-14 Resverlogix Corp. Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
US8436038B2 (en) 2007-08-17 2013-05-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
CN105130957A (zh) 2009-05-29 2015-12-09 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
AU2010319400B2 (en) 2009-11-16 2013-12-19 Eli Lilly And Company Spiropiperidine compounds as ORL-1 receptor antagonists
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
JP2016531874A (ja) 2013-09-26 2016-10-13 ファーマケア，インク． オートタキシン阻害剤化合物
EP3186225A4 (en) 2014-08-27 2018-02-28 The Governing Council of the University of Toronto Cannabinoid type 1 receptor modulators
US10654838B2 (en) 2014-10-08 2020-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aminopyridine compounds useful as inhibitors of protein prenylation
MX2017006437A (es) 2014-11-21 2017-08-08 Esteve Labor Dr Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
CN107949559B (zh) 2015-08-27 2020-12-11 辉瑞公司 作为irak4调节剂的双环稠合杂芳基或芳基化合物
EP3414247B1 (en) 2016-02-08 2021-04-21 F. Hoffmann-La Roche AG Spiroindolinones as ddr1 inhibitors
CA3103020A1 (en) 2018-04-30 2019-11-07 The Trustees Of Indiana University Compounds for modulating ddah and adma levels, as well as methods of using thereof to treat disease
KR20210116483A (ko) * 2018-12-17 2021-09-27 버텍스 파마슈티칼스 인코포레이티드 Apol1 억제제 및 그의 사용 방법
WO2020186220A1 (en) 2019-03-13 2020-09-17 Immunophage Biomedical Co., Ltd. Compounds as inhibitors of macrophage migration inhibitory factor
CN115087440A (zh) 2019-12-19 2022-09-20 卡斯玛治疗公司 Trpml调节剂
AU2021213758A1 (en) 2020-01-29 2022-09-01 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021158666A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
TWI865738B (zh) 2020-03-06 2024-12-11 美商維泰克斯製藥公司 治療apol-1依賴性局灶性節段性腎小球硬化之方法
CA3171950A1 (en) 2020-04-22 2021-10-28 David William Sheppard Collagen 1 translation inhibitors and methods of use thereof
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
US20230201201A1 (en) 2020-05-07 2023-06-29 Rambam Med-Tech Ltd. Composition for use in the treatment of apol1-associated disease
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
AU2021289750A1 (en) 2020-06-12 2023-02-02 Vertex Pharmaceuticals Incorporated Solid forms of APOL1 inhibitor and using the same
US20230014907A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
CR20230132A (es) 2020-08-26 2023-06-27 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos
EP4392426A1 (en) 2021-08-26 2024-07-03 Vertex Pharmaceuticals Incorporated Solid forms of spirotricyclic apol1 inhibitors and methods of using same

Also Published As

Publication number Publication date
IL318169A (en) 2025-03-01
CN116547287A (zh) 2023-08-04
UY39395A (es) 2022-03-31
IL300298A (en) 2023-04-01
CO2023003026A2 (es) 2023-03-17
US20240368180A1 (en) 2024-11-07
JP2023539194A (ja) 2023-09-13
ECSP23020167A (es) 2023-12-29
KR20230057386A (ko) 2023-04-28
US11866446B2 (en) 2024-01-09
IL300298B1 (en) 2025-02-01
MX2023002269A (es) 2023-05-16
US20220106327A1 (en) 2022-04-07
DOP2023000042A (es) 2023-07-09
PE20231106A1 (es) 2023-07-19
AU2021333776A1 (en) 2023-03-16
CA3190609A1 (en) 2022-03-03
EP4204423A1 (en) 2023-07-05
CL2023000536A1 (es) 2023-09-08
WO2022047031A1 (en) 2022-03-03
BR112023003423A2 (pt) 2023-03-21
TW202227456A (zh) 2022-07-16
AR123355A1 (es) 2022-11-23

Similar Documents

Publication Publication Date Title
CR20230132A (es) Inhibidores de apol1 y métodos para usar los mismos
ECSP24050151A (es) Derivados de 4-fenil-2-(1h-1,2,3-triazol-4-il)piperidin-4-ol como inhibidores de apol1 y métodos para usar los mismos
MX2021011606A (es) Compuestos dirigidos a prmt5.
CO2024012060A2 (es) Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos
SA521422270B1 (ar) Apol1 مثبطات لـ وطرق لاستخدامها
CL2021003202A1 (es) Compuestos de pirrolidina
CL2022003360A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578)
EA201691142A1 (ru) Ингибиторы мек и способы их применения
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
CO2024001367A2 (es) Compuestos antivirales
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
CO2024012058A2 (es) Derivados de 2-metil-4’,5’-dihidrospiro[piperidina-4,7’-tieno[2,3-c]pirano] como inhibidores de apol1 y métodos de uso de los mismos
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
CO2021017202A2 (es) Compuestos tricíclicos
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
CO2022014272A2 (es) Agente para el tratamiento de lesión renal aguda inducida por medio de contraste
UY39799A (es) Compuestos de pirrolil–sulfonamida
AR125358A1 (es) Inhibidores heteroaromáticos bicíclicos de la peptidasa 5 relacionada con la calicreína (klk5)
BR112022005706A2 (pt) Inibidores de 1,6-naftiridina substituída de cdk5
AR057403A1 (es) 4- anilino-3-quinolincarbonitrilos para el tratamiento del cancer
EA202192859A1 (ru) ПРОИЗВОДНЫЕ ТЕТРАГИДРО-1Н-ЦИКЛОПЕНТА[cd]ИНДЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА-2 (АЛЬФА), ИНДУЦИРУЕМОГО ГИПОКСИЕЙ
AR119967A1 (es) Degradadores bifuncionales de brd9 y sus métodos de uso